MBX Biosciences

Home
United States
Carmel, IN
MBX Biosciences

At MBX Biosciences, our mission is to help transform the lives of people living with obesity and rare endocrine disorders.

Using our peptide delivery platform, we are advancing a pipeline of novel Precision Endocrine Peptides (PEPs)™ designed to overcome key limitations of existing treatments and improve efficacy, tolerability, safety, and convenience. Our lead candidate, canvuparatide (MBX 2109) – a potential once-weekly parathyroid hormone (PTH) replacement therapy for the treatment of chronic hypoparathyroidism – is preparing for Phase 3 development. We are also advancing an obesity portfolio including MBX 4291, a GLP-1/GIP co-agonist prodrug in Phase 1 development, and MBX 5765, an amycretin prodrug in preclinical development. In addition, we are on track to nominate its GLP-1/GIP/GCG receptor prodrug candidate in Q3 2026, further expanding its obesity pipeline to potentially address the full spectrum of patient needs. Learn more about our pipeline and peptide delivery platform: www.mbxbio.com.

10/28/2026

At MBX, our mission to transform the lives of people impacted by endocrine and metabolic diseases guides how we continue to grow and invest for the future.

Last month, we celebrated the opening of our new office and laboratory facility in Burlington, Massachusetts, creating additional space to foster scientific innovation as we advance our pipeline.

“The opening of our Burlington site is an important investment in our people and the future of MBX,” said Steve Hoerter, Chief Executive Officer. “It gives our team greater capabilities to pursue the science that we believe can translate into meaningful new treatment options for patients.”

Learn more about our mission: https://mbxbio.com/about-us/

10/22/2026

After being diagnosed with hypoparathyroidism following thyroid surgery, Andrea faced the challenges of adjusting to life with a rare chronic condition while raising three young children and working full time.

From around-the-clock calcium supplementation and symptom monitoring to multiple emergency room visits, her story highlights the daily realities faced by many people living with hypoparathyroidism.

We're honored to highlight patients like Andrea who help raise awareness and support connection within the hypoparathyroidism community.

Learn more about MBX’s work in hypoparathyroidism and the unmet needs within rare endocrine diseases: https://mbxbio.com

10/09/2026

Last month, MBX colleagues came together for Together Week, a chance to strengthen connections across teams and spend time with the patients and communities that inspire our work every day.

We kicked off the week by volunteering with a Life Science Cares Boston partner, The Food Project at Baker Bridge Farm, helping support its efforts to grow and distribute fresh, locally grown food throughout the region. We also had the privilege of hearing from a patient advocate living with hypoparathyroidism, whose story was a powerful reminder of why we do what we do.

This Together Week also marked an exciting milestone for MBX with the opening of our new office and laboratory facility in Burlington, Massachusetts. The expanded space and growing in-house capabilities will support our continued research efforts and help us build new connections within the Boston biotech community.

We're grateful to everyone who helped make the week so meaningful and look forward to building on this momentum in the months ahead.

Learn more about our mission: mbxbio.com/about-us/

09/24/2026

It was a privilege to spend time with the hypoparathyroidism community at the 2026 International HypoPARA Conference in Phoenix last week.

The conference provided a valuable forum for members of our team to connect with patients, caregivers, advocates and health care professionals, hear their perspectives and better understand what matters most to this community.

Thank you to the HypoPARAthyroidism Association, Inc. for bringing the community together and creating an important space for connection, learning and support. We’re grateful to everyone who took the time to stop by our table and share their experiences.

09/23/2026

At MBX Biosciences, we're proud to partner with Life Science Cares Boston, an organization dedicated to mobilizing the life sciences community to disrupt the cycles of poverty and inequality through investments in education, economic opportunity and health equity.

Through volunteering, advocacy and community partnerships, Life Science Cares Boston is creating meaningful change for individuals and families across the region. We're honored to support their mission and contribute to efforts that strengthen our communities.

Learn more about Life Science Cares Boston and ways to get involved: https://lifesciencecares.org/boston/

09/21/2026

At MBX, we are advancing precision peptide therapies that address significant unmet needs in endocrine and metabolic diseases.

At the forefront of this effort is our Discovery team. Working across disciplines, they collaborate closely with colleagues in CMC, Clinical, Regulatory, Commercial and Intellectual Property to identify and progress new candidates with the potential to become transformative therapies.

The recent nomination of our once-monthly GLP-1/GIP/glucagon agonist prodrug candidate is the latest example of that work in action. This development candidate expands our growing obesity portfolio and reflects the strength of our discovery engine.

John Lee, Director, Chemistry at MBX Biosciences, shared what it means to help build the next wave of MBX's pipeline:

"This team represents an important investment in MBX’s future. Together, we bring the expertise, scientific curiosity and shared commitment needed to advance promising science that could make a meaningful difference for people living with endocrine and metabolic disorders.”

We are proud to spotlight some of the scientists and innovators behind these discoveries and the work helping shape the future of our pipeline.

Learn more about our pipeline: https://mbxbio.com/our-pipeline

08/27/2026

Today we are excited to announce that the first patient has been dosed in the pivotal Phase 3 oPTimize trial evaluating its once-weekly, investigational parathyroid hormone (PTH) replacement therapy for the treatment of adults with chronic hypoparathyroidism (HP).

The global registrational study will enroll approximately 160 patients and builds on positive Phase 2 Avail™ results and durable one-year data demonstrating sustained clinical benefit.

We look forward to advancing the oPTimize trial as we work to bring this potential therapy one step closer to people living with HP.

Read more about the Phase 3 oPTimize trial: https://investors.mbxbio.com/news-releases/news-release-details/mbx-biosciences-announces-first-patient-dosed-pivotal-phase-3

07/13/2026

By 2035, 25% of the global population is projected to have obesity.

Meanwhile, many patients discontinue current treatments within 1–2 years – often driven by GI-related tolerability issues– highlighting the need for additional options.

Katherine Saunders, MD, FTOS, Co-Founder at FlyteHealth and Clinical Assistant Professor at Weill Cornell Medicine, shared these insights at our recent Obesity Day for investors.

At MBX Biosciences, we’re working to advance precision peptide therapies to help address these challenges for people living with obesity.

Learn more: https://investors.mbxbio.com/news-events/events

06/22/2026

As the biotech industry marks 50 years of progress, MBX is proud to support the Biotechnology Innovation Organization - BIO’s campaign – spotlighting the breakthroughs, patients, and scientists driving innovation forward.

We are proud to be part of an industry that has transformed lives over the past five decades and look forward to contributing to continued progress as we advance scientific innovation for people living with rare endocrine and metabolic diseases through our Precision Endocrine Peptide (PEP)™ platform.

Explore the impact of biotech over the past 50 years: fightofourlives.com/timeline

06/01/2026

June 1 marks – an opportunity to spotlight hypoparathyroidism (HP) and the more than 100,000 people in the U.S. living with this rare endocrine disorder.

At MBX, we’re proud to partner with the HypoPARAthyroidism Association, Inc.], whose dedicated efforts support patients and families through education, community, research, and advocacy.

While awareness days play an important role, the need for progress in HP extends well beyond a single moment. We remain committed to advancing the science and leveraging our Precision Endocrine Peptide (PEP™) platform to help address the ongoing unmet needs of people living with HP.

Address

Carmel, IN

Website

https://mbxbio.com/

Alerts

Be the first to know and let us send you an email when MBX Biosciences posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.